David A. Driver
20Patents
15h-index
23Co-inventors
81Inventor score
Filing activity: Mar 15, 1995 → May 31, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5814482A | Eukaryotic layered vector initiation systems | Emerging Cross-Sectional Technologies | 202 | Expired |
| US5843723A | Alphavirus vector constructs | Emerging Cross-Sectional Technologies | 162 | Expired |
| US5789245A | Alphavirus structural protein expression cassettes | Emerging Cross-Sectional Technologies | 150 | Expired |
| US6015686A | Eukaryotic layered vector initiation systems | Emerging Cross-Sectional Technologies | 127 | Expired |
| US6376236B1 | Recombinant alphavirus particles | Emerging Cross-Sectional Technologies | 61 | Expired |
| US6342372B1 | Eukaryotic layered vector initiation systems for production of recombinant proteins | Emerging Cross-Sectional Technologies | 41 | Expired |
| US8541369B2 | Fibroblast growth factor 21 variants having improved pharmacological potency and/or improved pharmaceutical stability | Human Necessities | 40 | Active |
| US8883726B2 | Fibroblast growth factor 21 variants | Human Necessities | 39 | Active |
| US8927492B2 | Fibroblast growth factor 21 proteins | Chemistry; Metallurgy | 38 | Active |
| US8741841B2 | Fibroblast growth factor 21 proteins | Chemistry; Metallurgy | 37 | Active |
| US7977091B2 | Eukaryotic layered vector initiation systems | Emerging Cross-Sectional Technologies | 36 | Active |
| US7771979B2 | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems | Chemistry; Metallurgy | 32 | Active |
| US6013517A | Crossless retroviral vectors | Chemistry; Metallurgy | 28 | Expired |
| US6333195A | Crossless retroviral vectors | Chemistry; Metallurgy | 21 | Expired |
| US8647864B2 | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems | Chemistry; Metallurgy | 19 | Active |
| US7572628B2 | Eukaryotic layered vector initiation systems | Emerging Cross-Sectional Technologies | 10 | Expired |
| US10011653B2 | Antibodies to tau and methods of treatment therewith | Emerging Cross-Sectional Technologies | 5 | Active |
| US9527909B2 | Antibodies to tau and uses thereof | Emerging Cross-Sectional Technologies | 3 | Active |
| US9422353B2 | Fibroblast growth factor 21 variant, composition , and uses thereof | Human Necessities | 2 | Active |
| US10808027B2 | DNA molecules encoding antibodies to tau and methods of making thereof | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.